MedPanel Report Solicits Expert Opinion On The Future Of Stem Cell Research
WALTHAM, MA--(INTERNET WIRE)--Aug 17, 2001-- Stem cell research has become the subject of intense debate, with vocal opposition to the use of fetal stem cells at the center. Although the Bush administration has endorsed limited funding for stem cell research, the subject remains steeped in controversy. Among the key questions left unanswered are:
*How likely is a major breakthrough in stem cell research in the next decade?

*Would such a breakthrough diminish opposition to the technology, thus paving the way for more funding?

Decision Resources, Inc., in partnership with MedPanel, Inc., announces the publication of MedPanel TrendCast: Stem Cell Therapeutics, a new report that offers first-hand knowledge and opinions on the future of this potentially revolutionary technology.

MedPanel TrendCast: Stem Cell Therapeutics is the result of an online discussion that progressed over a two-week period in May 2001. The discussion participants included 11 physicians who are specialists in cardiology, ophthalmology, dermatology, and orthopedics--areas where tissue engineering has tremendous potential, and in some cases, has already resulted in marketed products. The discussion was structured to elicit the panel's views of the application of emerging stem cell technologies to a variety of diseases, including macular degeneration, corneal diseases, cardiovascular disease, congestive heart failure, cardiac valvular disease, long QT syndrome, some dyslipidemias, hypertrophic cardiomyopathy, osteoarthritis, bone fractures, traumatic neurological injury of the spinal cord or brain, burns, and other conditions resulting in excessive skin loss. The following areas were evaluated:

*The use of fetal versus adult stem cells.

*Obstacles to development given the current political climate surrounding stem cell research.

*Hurdles to the widespread use of such products once they reach the market.

*The impact of stem cell technologies on solid organ transplantation.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at


Cindy Ohlman

Francoise Bidart

Makiko Yoshimoto

Alice Von Loesecke
Decision Resources, Inc.

Email this story - Most-emailed articles - Most-viewed articles